Literature DB >> 19900687

Vaccinia virus A43R gene encodes an orthopoxvirus-specific late non-virion type-1 membrane protein that is dispensable for replication but enhances intradermal lesion formation.

Cindy L Sood1, Bernard Moss.   

Abstract

The vaccinia virus A43R open reading frame encodes a 168-amino acid protein with a predicted N-terminal signal sequence and a C-terminal transmembrane domain. Although A43R is conserved in all sequenced members of the orthopoxvirus genus, no non-orthopoxvirus homolog or functional motif was recognized. Biochemical and confocal microscopic studies indicated that A43 is expressed at late times following viral DNA synthesis and is a type-1 membrane protein with two N-linked oligosaccharide chains. A43 was present in Golgi and plasma membranes but only a trace amount was detected in sucrose gradient purified mature virions and none in CsCl gradient purified enveloped virions. Prevention of A43R expression had no effect on plaque size or virus replication in cell culture and little effect on virulence after mouse intranasal infection. Although the A43 mutant produced significantly smaller lesions in skin of mice than the control, the amounts of virus recovered from the lesions were similar.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900687      PMCID: PMC3725038          DOI: 10.1016/j.virol.2009.10.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

1.  Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome.

Authors:  Chris Upton; Stephanie Slack; Arwen L Hunter; Angelika Ehlers; Rachel L Roper
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  Improved prediction of signal peptides: SignalP 3.0.

Authors:  Jannick Dyrløv Bendtsen; Henrik Nielsen; Gunnar von Heijne; Søren Brunak
Journal:  J Mol Biol       Date:  2004-07-16       Impact factor: 5.469

3.  Respiratory infection of mice with vaccinia virus.

Authors:  G S Turner
Journal:  J Gen Virol       Date:  1967-07       Impact factor: 3.891

4.  A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae.

Authors:  David C Tscharke; Geoffrey L Smith
Journal:  J Gen Virol       Date:  1999-10       Impact factor: 3.891

5.  Vaccinia virus semaphorin A39R is a 50-55 kDa secreted glycoprotein that affects the outcome of infection in a murine intradermal model.

Authors:  Jeremy D Gardner; David C Tscharke; Patrick C Reading; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2001-09       Impact factor: 3.891

6.  The vaccinia virus A14.5L gene encodes a hydrophobic 53-amino-acid virion membrane protein that enhances virulence in mice and is conserved among vertebrate poxviruses.

Authors:  T Betakova; E J Wolffe; B Moss
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Vaccinia virus E2L null mutants exhibit a major reduction in extracellular virion formation and virus spread.

Authors:  Arban Domi; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

Review 8.  Pathogen-derived immunomodulatory molecules: future immunotherapeutics?

Authors:  Padraic G Fallon; Antonio Alcami
Journal:  Trends Immunol       Date:  2006-08-21       Impact factor: 16.687

9.  Vaccinia virus gene F3L encodes an intracellular protein that affects the innate immune response.

Authors:  Graham C Froggatt; Geoffrey L Smith; Philippa M Beard
Journal:  J Gen Virol       Date:  2007-07       Impact factor: 3.891

10.  Structure and function of A41, a vaccinia virus chemokine binding protein.

Authors:  Mohammad W Bahar; Julia C Kenyon; Mike M Putz; Nicola G A Abrescia; James E Pease; Emma L Wise; David I Stuart; Geoffrey L Smith; Jonathan M Grimes
Journal:  PLoS Pathog       Date:  2008-01       Impact factor: 6.823

View more
  1 in total

1.  Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.

Authors:  Naif Khalaf Alharbi; Alexandra J Spencer; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.